

Biocon Biologics South Africa (Pty) Ltd.**BALANCE SHEET AS AT MARCH 31, 2026**

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2026</u>	<u>March 31, 2025</u>
ASSETS			
Non-current assets			
Income-tax asset (net)		382	220
Deferred tax asset (net)		6	3
Total non-current assets		388	223
Current assets			
Financial assets			
(i) Trade receivables	1	5,113	4,811
(ii) Cash and cash equivalents	2	1,202	1,466
Other current assets	3	1,068	820
Total current assets		7,383	7,097
TOTAL		7,771	7,320
EQUITY AND LIABILITIES			
Equity			
Equity share capital	4	-	-
Other equity	5	960	526
Total equity		960	526
Current liabilities			
Financial liabilities			
(i) Trade payables	6	6,370	6,460
Income-tax liability (net)		366	191
Provisions	7	67	58
Other current liabilities	8	8	85
Total current liabilities		6,811	6,794
TOTAL		7,771	7,320

Biocon Biologics South Africa (Pty) Ltd.**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	Year ended March 31, 2026	Year ended March 31, 2025
Income			
Revenue from operations	9	6,602	7,505
Other operating income	10	6	52
Total revenue (I)		6,608	7,557
Expenses			
Employee benefits expense	11	5,313	5,437
Other expenses	12	689	1,438
Total expenses (II)		6,002	6,875
Profit before tax		606	682
Tax expense			
Current tax		174	187
Deferred Tax		(2)	(3)
Total tax expense		172	184
Profit for the period		434	498

Biocon Biologics South Africa (Pty) Ltd.

STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2026

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
I Cash flows from operating activities		
Profit after tax	434	498
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Tax expense	172	184
Operating profit before working capital changes	606	682
Movements in working capital		
(Increase) in trade receivables	(303)	(4,505)
(Increase) in other assets	(248)	(820)
(Decrease)/Increase in trade payable, other liabilities and provisions	(158)	6,311
Cash (used in) / generated from operations	(103)	1,668
Direct taxes paid	(161)	(220)
Net cash flow (used in) / generated from operating activities	(264)	1,448
II Cash flows from investing activities		
Net cash flow (used in) investing activities	-	-
III Cash flows from financing activities		
Proceeds from issue of equity shares	-	-
Net cash flow generated from financing activities	-	-
IV Net (decrease)/increase in cash and cash equivalents (I + II + III)	(264)	1,448
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI Cash and cash equivalents at the beginning of the year	1,466	18
VIII Cash and cash equivalents at the end of the year (IV + V + VI)	1,202	1,466
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	1,202	1,466
Total cash and cash equivalents	1,202	1,466

Biocon Biologics South Africa (Pty) Ltd.**Notes to financial statements for the year ended March 31, 2026**

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
1. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	5,113	4,811
	5,113	4,811
2. Cash and cash equivalents		
Balances with banks:		
On current accounts	1,202	1,466
	1,202	1,466
3. Other current assets		
Prepayments	9	11
Balances with statutory/government authorities	760	728
Others	129	81
	1,068	820
4. Share capital		
Equity share capital	-	-
	-	-
5. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	508	10
Profit / (Loss) for the period	434	498
Net surplus/(deficit) in the statement of profit and loss	942	508
Securities Premium	18	18
Total other equity	960	526
6. Trade payables	6,370	6,460
7. Provisions		
Current		
Compensated absences	67	58
	67	58
8. Other liabilities		
(a) Current liabilities		
Statutory liabilities	8	85
	8	85

Biocon Biologics South Africa (Pty) Ltd.**Notes to financial statements for the year ended March 31, 2026**

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
9. Revenue from operations		
Sale of Services		
Support service cross charge to Group Companies	6,602	7,505
	6,602	7,505
10. Other operating income		
Foreign exchange fluctuations, net	6	52
	6	52
11. Employee benefits expense		
Salaries, wages and bonus	5,313	5,437
	5,313	5,437
12. Other expenses		
Rates and taxes	48	72
Legal and professional fees	158	748
Repair and Maintenance	3	-
Research and development expenses	5	-
Travelling and conveyance	302	568
Sales promotion expenses	15	11
Printing and stationery	10	10
Communication expenses	19	11
Miscellaneous expenses	29	18
Insurance Charges	100	-
	689	1,438